Following our strategy of partnering in research and increasing our understanding of the biological processes underlying brain diseases, Lundbeck joins a big project that will work to identify biomarkers for Alzheimer’s disease.
The project focuses on identifying specific proteins that floats from the brain and into the cerebrospinal fluid as the brain degenerates as it does in Alzheimer’s disease. Measuring the amount of proteins should then give an indication of the stage of the disease.
This new understanding of Alzheimer’s disease progression will help improve the monitoring of early Alzheimer’s disease and a patient’s response to treatment. As such the project has the potential to revolutionize clinical trials and lead to the development of targeted therapies for Alzheimer’s disease patients.
Led by The Foundation for the National Institutes of Health in the US the project brings together authorities, universities and companies. Among the participants are the U.S. Food and Drug Administration, the National Institute of Mental Health and Yale School of Medicine.
Read more: https://fnih.org/news/announcements/alzheimers-progression-and-treatment-response
Full list of partners:
University of Pennsylvania
U.S. Food and Drug Administration
Yale School of Medicine
National Institute on Aging
National Institute of Mental Health